Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dual-targeting

Liang, Yaoyao; Peng, Jian; Li, Ning; Yu‐Wai‐Man, Cynthia; Wang, Qian; Xu, Yuhong; Wang, Hongxia; Tagalakis, Aristides D.; Du, Zongliang

doi:10.1016/j.nano.2018.09.018

Cited by 25 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These NPs effectively penetrated the ECM and accumulated in the tumor due to the enhanced EPR effect, as demonstrated by low-intensity focused ultrasound (LIFU) imaging. Furthermore, dual targeting strategies with EGFR and CD44 have recently become a focus of research for the EPR effect enhancement 43, 44. Although the dual combination of EGFR and HA targeting has not yet been widely studied, it has appeared as an efficacious way for tumor-targeted therapy to decrease the uncertainty of single targeting.…”

Section: Utilization Of Tme-specific Molecular Markersmentioning

confidence: 99%

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

et al. 2019

View full text Add to dashboard Cite

The use of nanomedicine for cancer treatment takes advantage of its preferential accumulation in tumors owing to the enhanced permeability and retention (EPR) effect. The development of cancer nanomedicine has promised highly effective treatment options unprecedented by standard therapeutics. However, the therapeutic efficacy of passively targeted nanomedicine is not always satisfactory because it is largely influenced by the heterogeneity of the intensity of the EPR effect exhibited within a tumor, at different stages of a tumor, and among individual tumors. In addition, limited data on EPR effectiveness in human hinders further clinical translation of nanomedicine. This unsatisfactory therapeutic outcome in mice and humans necessitates novel approaches to improve the EPR effect. This review focuses on current attempts at overcoming the limitations of traditional EPR-dependent nanomedicine by incorporating supplementary strategies, such as additional molecular targeting, physical alteration, or physiological remodeling of the tumor microenvironment. This review will provide valuable insight to researchers who seek to overcome the limitations of relying on the EPR effect alone in cancer nanomedicine and go “beyond the EPR effect”.

show abstract

Section: Utilization Of Tme-specific Molecular Markersmentioning

confidence: 99%

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Polyethyleneimine based GE11 conjugated nanoparticles delivered this gene into the colon cancer xenografts, which enabled bioimag ing as well as suppressed tumor growth [233]. The lipo somes loaded with miRNAs to inactivate survivin that carried two ligands -GE11 targeting EGFR and hyaluronic acid targeting CD44 -inhibited growth of the hepatocellular carcinoma xenografts [234]. It must be also emphasized that EGFR especially its mutant variant EGFRvIII that forms a unique epitope, have been exten sively examined including in several clinical trials for their potential use in CAR T cell therapy [235].…”

Section: The Use Of Egfr As a Delivery Systemmentioning

confidence: 99%

Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

Rosenkranz

Slastnikova

2020

Biochemistry Moscow

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is an integral surface protein mediating cellular response to a number of growth factors. Its overexpression and increased activation due to mutations is one of the most common traits of many types of cancer. Development and clinical use of the agents, which block EGFR activation, became a prime example of the personalized targeted medicine. However, despite the obvious success in this area, cancer cure remains unattainable in most cases. Because of that, as well as the result of the search for possible ways to overcome the difficulties of treatment, a huge number of new treatment methods relying on the use of EGFR overexpression and its changes to destroy cancer cells. Modern data on the structure, functioning, and intracellular transport of EGFR, its natural ligands, as well as signaling cascades triggered by the EGFR activation, peculiarities of the EGFR expression and activation in oncological disorders, as well as applied therapeutic approaches aimed at blocking EGFR signaling pathway are summarized and analyzed in this review. Approaches to the targeted delivery of various chemotherapeutic agents, radionuclides, immunotoxins, photosensitizers, as well as the prospects for gene therapy aimed at cancer cells with EGFR overexpression are reviewed in detail. It should be noted that increasing attention is being paid nowadays to the development of multifunctional systems, either carrying several different active agents, or possessing several environment-dependent transport functions. Potentials of the systems based on receptor-mediated endocytosis of EGFR and their possible advantages and limitations are discussed.

show abstract

“…EGFR is an important factor in HCC and previous studies have demonstrated that EGFR is involved in various HCC mechanisms including cell proliferation, latestage metastasis, treatment and drug resistance. [30][31][32][33][34][35] However, anti-EGFR agencies do not show ideal results in HCC involving extremely complicated pathways. 10,12 Lin et al reported that the anti-EGFR drug resistance in HCC is caused by the promoted interaction of EGFR with mTORC2.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab

Wang¹,

Zhang

Gong

et al. 2021

IJGM

View full text Add to dashboard Cite

Introduction Hepatocellular carcinoma (HCC) continues to be a cancer with rising incidence, high mortality, and recurrence rate. The therapeutic effects on HCC are not satisfactory currently. Epidermal growth factor receptor (EGFR) is an important factor, while anti-EGFR agencies have not shown ideal results in HCC. Materials and Methods We tested efficacy of nimotuzumab and EGFR expression on cell surface in six HCC cell lines (Hep 3B2.1–7, Li-7, PLC/PRF/5, SK-HEP-1, SNU-182, and SNU-387). Then, we analyzed RNA sequences of every cell line and performed a bioinformatic analysis. Differentially expressed genes (DEGs) were analyzed. The data, TCGA-LIHC from The Cancer Genome Atlas (TCGA) and GSE102079 from Gene Expression Omnibus (GEO), were used to analyse DEGs of Hoshida subclass. Results Hep 3B2.1–7 and PLC/PRF/5 were sensitive to nimotuzumab whereas Li-7, SK-HEP-1, SNU-182, and SNU-387 cell lines were resistant. Then, we compared the DEGs between sensitive and resistant group cell lines. We enriched DEGs in GO and KEGG and performed GSEA in each group. Genes in two groups did not show obvious different expressions in EGFR pathways, while Hoshida subclass of HCC seemed to associate with the efficacy of nimotuzumab in that S2 and S3 showed better therapeutic effect than S1. Therefore, we analyzed genes in human tumor samples which were from TCGA-LIHC and GSE102079. We found that COL1A1, COL1A2, COL3A1, and MMP9 were the focus DEGs of S1 and S2 & S3 related to EGFR. Conclusion The efficacy of nimotuzumab in HCC did not show direct relevance with EGFR protein expression and EGFR-related pathway. However, efficacy could associate with Hoshida subclass of HCC. Three ECM genes (COL1A1, COL1A2, COL3A1) and MMP9 were paid attention, as they might play important roles in the curative effect of nimotuzumab in HCC.

show abstract

Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dual-targeting

Cited by 25 publications

References 38 publications

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab

Contact Info

Product

Resources

About